Department of Medical Microbiology, Faculty of Medicine, University Malaya, Kuala Lumpur 50603, Malaysia.
Department of Medical Microbiology, Faculty of Medicine, University Malaya, Kuala Lumpur 50603, Malaysia.
Vaccine. 2021 May 21;39(22):2983-2988. doi: 10.1016/j.vaccine.2021.04.010. Epub 2021 Apr 28.
Acute respiratory infections (ARI) are a major cause of morbidity and mortality in Malaysian children < 5 years. Knowledge of associated economic costs is important for policymakers to determine cost-effectiveness of interventions, such as pneumococcal or influenza vaccines, which are underused in Malaysia.
Children < 5 years admitted with ARI to a teaching hospital in Kuala Lumpur were prospectively recruited between July 2013 and July 2015. Medical (with and without government subsidies), non-medical and indirect costs from pre-admission, admission and post-discharge were obtained by interviews with carers and from medical records. Respiratory viruses were diagnosed by immunofluorescence and virus culture.
200 patients were recruited, and 74 (37%) had respiratory viruses detected. For each admitted ARI, the median direct out-of-pocket cost (subsidized) was USD 189 (interquartile range, 140-258), representing a median 16.4% (10.4-22.3%) of reported monthly household income. The median total direct cost (unsubsidized) was USD 756 (564-987), meaning that government subsidies covered a median 75.2% (70.2-78.4%) of actual costs. Median direct costs for 50 respiratory syncytial virus (RSV) cases were higher than the 126 virus-negative cases (USD 803 vs 729, p = 0.03). The median societal cost (combining direct and indirect costs) was USD 871 (653-1,183), which is 1.8 times the Malaysian health expenditure per capita in 2014. Costs were higher with younger age, presence of comorbidity, prematurity, and detection of a respiratory virus.
These comprehensive estimated costs of ARI admissions in children < 5 years are high. These costs can be used as a basis for planning treatment and preventive strategies, including cost-effectiveness studies for influenza and, in future, RSV vaccines.
急性呼吸道感染(ARI)是导致马来西亚 5 岁以下儿童发病和死亡的主要原因。了解相关经济成本对于决策者确定干预措施的成本效益至关重要,例如在马来西亚未被充分利用的肺炎球菌或流感疫苗。
2013 年 7 月至 2015 年 7 月,前瞻性招募吉隆坡一所教学医院因 ARI 入院的 5 岁以下儿童。通过对照顾者的访谈和病历,获得了入院前、入院期间和出院后的医疗(有和没有政府补贴)、非医疗和间接费用。通过免疫荧光和病毒培养诊断呼吸道病毒。
共招募了 200 名患者,其中 74 名(37%)检测到呼吸道病毒。对于每例入院的 ARI,直接自付费用中位数(补贴后)为 189 美元(四分位距,140-258),占报告月家庭收入中位数的 16.4%(10.4-22.3%)。未补贴的直接总费用中位数为 756 美元(564-987),这意味着政府补贴涵盖了实际费用的中位数 75.2%(70.2-78.4%)。50 例呼吸道合胞病毒(RSV)病例的直接费用中位数高于 126 例病毒阴性病例(803 美元比 729 美元,p=0.03)。结合直接和间接成本的社会成本中位数为 871 美元(653-1183),是 2014 年马来西亚人均卫生支出的 1.8 倍。年龄较小、合并症、早产和呼吸道病毒检测的患者,其成本更高。
这些对 5 岁以下儿童 ARI 入院综合估计成本较高。这些成本可用于制定治疗和预防策略的基础,包括流感疫苗的成本效益研究,以及未来的 RSV 疫苗。